Merck’s Forward P/E Nearly Doubled to 17x in a Year. Here’s What Its Pipeline Must Deliver by 2030

Summary

Merck's forward P/E ratio has nearly doubled to 17x over the past year, raising questions about pipeline delivery expectations through 2030. The article discusses valuation metrics related to the company's drug development prospects.